Pluristem’s PLX cells show promise in treating limb ischemia

The company says it could be tapping into a potential market of over $1 billion.

PLX cells are placenta derived mesenchymal stem cells expanded in the company’s proprietary PluriX 3-D bioreactor system.

Scientists administered Pluristem’s proprietary PLX cells in vivo to one set of ischemic mice. Post-treatment evaluation using Doppler technology indicated revascularization of the limb treated with PLX cells but not in those that were not treated with PLX. The hind legs of mice were rendered ischemic using standard industry methodologies.

The company says current therapeutic methodologies have proven ineffective for many severe limb ischemic situations and led the medical community to call for the development of cellular therapies, such as Pluristem’s PLX cells and other methods as alternative treatments.